Health economic outcomes in migraine: Impact of zolmitriptan

Reviews in Contemporary Pharmacotherapy

Volumn 11, Issue 2, 2000, Pages 133-138

  Meddis, David ^a   Sawyer, James P C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; ZOLMITRIPTAN;

DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH ECONOMICS; HUMAN; MIGRAINE; QUALITY OF LIFE; REVIEW;

EID: 0034058558     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. Br Med J 1994; 309: 765-769.
2. Baker A, Sawyer J. Impact of zolmitriptan on migraineur life style - an observational study. J Outcomes Res 1999; 3: 1-9.
3. Björk S, Roos P. Economic aspects of migraine in Sweden. Stockholm: Swedish Institute for Health Economics, 1991.
4. Blau JN, Drummond MF. Migraine. London: Office of Health Economics, 1991.
5. Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiological study in young adults. J Psychiatr Res 1993; 27: 211-221.
6. Buring JE, Herbert P, Romero J et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995; 52: 129-134.
7. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. Q J Med 1996; 89: 77-84.
8. Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103-115.
9. Dahlöf C. Assessment of health-related quality of life in migraine. Cephalalgia 1993; 13: 233-237.
10. Dahlöf C, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31-36.
11. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-137.
12. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R. A nationwide survey of migraine in France: prevalence and clinical features in adults. Cephalalgia 1992; 12: 229-237.
13. Hurst BC, Patrick DL. Quality of life improvements in responders to long-term treatment with Zomig. Headache 1998; 38: 397.
14. Lipton RB. Simplifying migraine management through disability assessment. Choosing the right treatment: a simplified approach. Presented at the 4th Congress of the European Federation of Neurological Societies. Lisbon. Portugal, 7-11 September, 1999.
15. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993; 43: S6-S10.
16. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 152: 1273-1278.
17. Malmberg I. Evaluation of the cost-effectiveness of zolmitriptan for the acute treatment of migraine. Abstract and poster presented at the 15th Annual Meeting of the International Society of Technology Assessment in Health Care. Edinburgh, Scotland, 20-23 June, 1999.
18. 1B/1D agonist for migraine. Cephalalgia 1997; 17 (Suppl 18): 4-14.
19. McKenna S, Patrick D. Development of a migraine-specific quality of life measure for multi-national clinical trials. Abstract and poster presented at the 7th Congress of The International Headache Society, Toronto, Canada, 1995. Cephalalgia 1995; 15 (Suppl 14): 280.
20. McKenna SP, Doward LC, Mackenzie Davey K. The development and psychometric properties of the MSQOL: a migraine-specific quality of life instrument. Clin Drug Invest 1998; 15: 413-423.
21. Meddis D, Langham S. Patient satisfaction with zolmitriptan for the acute treatment of migraine. Abstract and poster presented at the 4th European Federation of Neurological Studies. Lisbon, 7-11 September, 1999.
22. Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990; 47: 849-853.
23. Michel P, Dartigues JF, Líndoulsi A, Henry P. Loss of productivity and quality of life in migraine sufferers among French workers: results of the GAZEL cohort. Headache 1997; 37: 71-78.
24. Michel P, Dartigues JF, Durn G, Moreau J, Salamon R, Henry P. Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 1999; 19: 503-510.
25. Mounstephen AH, Harrison RK. A study of migraine and its effects in a working population. Occup Med (Lond) 1995; 45: 311-317.
26. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994; 23: 1020-1026.
27. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67-76.
28. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337-343.
29. Ottman R, Lipton RB. Comorbidity of migraine and epilepsy. Neurology 1994; 44: 2105-2110.
30. Parry TG. The prevalence and costs of migraine in Australia. CAER Working Paper 1992/1. University of New South Wales, 1992.
31. Patrick DL, Hurst BC. Instrument development: migraine-specific quality of life measure (MSQOL). Med Outcomes Trust Bull 1998a; 6: 18-19.
32. Patrick DL, Hurst BC. Further development and testing of a migraine-specific quality-of-life measure (MSQOL). Neurology 1998b; 50 (Suppl 4): 301-302.
33. Patrick DL, Hurst BC. Consistency of MMR and QoL in migraine patients receiving long term treatment with 'Zomig'. Eur J Neurol 1998c; 5 (Suppl 3): 50.
34. Patrick DL, Hurst BC. Consistency of meaningful migraine relief and quality of life in patients treated with Zomig. Headache I998d; 38: 397.
35. Pfaffenrath V, Mauskop A, Tepper SJ. Zolmitriptan: reliable relief of migraine symptoms with early onset of action. Cephalalgia 1999; 19: 370.
36. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci 1992; 19: 333-339.
37. Rapoport AM, Ryan R. Zolmitriptan provides rapid and sustained relief of migraine headache. Cephalalgia 1999; 19: 370-371.
38. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991; 44: 1147-1157.
39. 1B/1D agonist: an overview of efficacy. Cephalalgia 1997; 17 (Suppl 18): 28-40.
40. Smith R. Impact of migraine on the family. Headache 1998; 38: 423-426.
41. Smith RC. Impact of migraine on the family. Headache 1996; 36: 278.
42. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study instrument. Headache 1993; 33: 351-358.
43. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of The 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219-1225.
44. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29-35.
45. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
46. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology 1996; 47: 52-59.
47. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population based sample of headache sufferers. Cephalalgia 1999; 19: 107-114.
48. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Manage Care 1996; 2: 139-143.
49. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38: 173-183.
50. Tuchman MM, Dowson AJ, Millson DS, Fletcher PE. Maximizing migraine relief with zolmitriptan: final data from an open-label study with >49 000 treated attacks. Abstract and poster presented at the 50th Annual Meeting of the American Academy of Neurology. Minneapolis, 25 April - 2 May, 1998.
51. Wagner TH, Patrick DL, Galer BS, Berzon RA. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 1996; 36: 484-492.